Molbio Diagnostics IPO Files RHP: Temasek, Motilal Oswal-Backed Firm to Open Issue August 10
- August 4, 2026
- Posted by: Ankit Jaiswal
- Category: IPO
Molbio Diagnostics IPO opens August 10. Fresh issue Rs 200 crore. OFS 91.66 lakh shares. Goa-headquartered, backed by Temasek and Motilal Oswal.
The Molbio Diagnostics IPO has moved a step closer to launch, with the Goa-headquartered diagnostics company filing its Red Herring Prospectus (RHP) ahead of the issue opening on August 10, 2026.
Click Here – Get Free Investment Predictions
Through the Molbio Diagnostics IPO, the company is raising Rs 200 crore via a fresh issue of shares, while existing shareholders will sell 91.66 lakh shares through an offer-for-sale. The issue counts Temasek and Motilal Oswal among its backers, lending institutional credibility to the offering ahead of its market debut on the exchanges.
| Detail | Value |
|---|---|
| Fresh issue size | Rs 200 crore |
| Offer for sale | 91.66 lakh shares |
| Headquarters | Goa, India |
| Key backers | Temasek, Motilal Oswal |
| Subscription opening date | August 10, 2026 |
Molbio Diagnostics IPO: Company Background
Molbio Diagnostics is known for its point-of-care molecular diagnostics platforms, including the Truenat range of portable testing devices used for infectious disease detection. The company gained wide recognition during the COVID-19 pandemic for its rapid, low-cost molecular testing solutions deployed across India and other emerging markets, a track record that features prominently in the case being built ahead of the offering. The company’s technology has since expanded into testing for tuberculosis, HIV and other infectious diseases beyond its pandemic-era product line.
Track upcoming IPOs and use Univest Screeners for research
Molbio Diagnostics IPO: Grey Market Premium (GMP)
Univest does not publish or track live grey market premium (GMP) figures for the Molbio Diagnostics IPO or any other issue. If you want to check the current unofficial GMP trend for this offering, you can refer to dedicated IPO-tracking platforms such as InvestorGain, Chittorgarh or IPO Watch, which publish these figures separately.
It is worth remembering that GMP is an unofficial, unregulated indicator quoted in the grey market and is not always an accurate predictor of listing-day performance. Investors should base their decision on the company’s fundamentals, financials and valuation rather than on GMP figures alone.
Download the Univest iOS App or Univest Android App to track upcoming IPO listings and live market updates.
What to Watch Ahead of the Molbio Diagnostics IPO
With the RHP now filed, investors should watch for the price band announcement, anchor investor allocation details, and the final subscription dates as the Molbio Diagnostics IPO approaches its August 10 opening. The presence of marquee investors like Temasek in the existing shareholder base is often viewed as a positive signal, though it does not by itself determine listing-day performance, and prospective applicants should review the full risk factors section of the prospectus once it is publicly available, alongside the company’s revenue trends and profitability profile over recent fiscal years.
Conclusion
The Molbio Diagnostics IPO, backed by Temasek and Motilal Oswal, has filed its RHP and is set to open on August 10, 2026, raising Rs 200 crore through a fresh issue alongside an offer-for-sale. Investors should study the full prospectus once available, avoid relying on unofficial GMP figures, and consult a SEBI-registered advisor before applying, given how quickly offer document details can evolve.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
When does the Molbio Diagnostics IPO open?
Ans. The Molbio Diagnostics IPO is set to open for subscription on August 10, 2026.
How much is the Molbio Diagnostics IPO fresh issue worth?
Ans. The Molbio Diagnostics IPO includes a fresh issue worth Rs 200 crore, alongside an offer-for-sale of 91.66 lakh shares by existing shareholders.
Who are the key investors backing Molbio Diagnostics?
Ans. The Molbio Diagnostics IPO is backed by Temasek and Motilal Oswal among its existing shareholders.
Where is Molbio Diagnostics headquartered?
Ans. Molbio Diagnostics is headquartered in Goa, India, and is known for its point-of-care molecular diagnostics platforms.
Where can I check GMP for the Molbio Diagnostics IPO?
Ans. Univest does not track GMP figures. You can check unofficial grey market premium trends on dedicated IPO-tracking platforms, keeping in mind GMP is not always an accurate predictor of listing performance.
What is Molbio Diagnostics known for?
Ans. Molbio Diagnostics is known for its Truenat range of portable molecular testing devices, widely used for infectious disease detection, including during the COVID-19 pandemic.
How can I apply for the Molbio Diagnostics IPO?
Ans. Once the price band and subscription dates are announced, investors can apply for the Molbio Diagnostics IPO through their bank’s ASBA facility or a broker-supported UPI application.
Is the Molbio Diagnostics IPO a mainboard or SME issue?
Ans. Given the Rs 200 crore fresh issue size and backing from institutional investors like Temasek, the Molbio Diagnostics IPO is structured as a mainboard listing rather than an SME issue.
